Felix Durand-Blanc

Villejuif, 94805, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial.

Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial.

Journal: JCO precision oncology

Published: January 14, 2026

Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer.

Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer.

Journal: JCO oncology practice

Published: November 24, 2025

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

Journal: NPJ precision oncology

Published: November 21, 2025

Will AI write the next 'Chapter' in literature reviews?

Will AI write the next 'Chapter' in literature reviews?

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 24, 2025

Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure.

Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure.

Journal: British journal of cancer

Published: August 06, 2025

ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 24, 2025

Predictive biomarkers of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer.

Predictive biomarkers of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer.

Journal: Therapeutic advances in medical oncology

Published: July 10, 2025

Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era.

Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era.

Journal: NPJ genomic medicine

Published: June 18, 2025

Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).

Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).

Journal: British journal of cancer

Published: May 05, 2025

Clearer Horizons: The latest advances in clear cell ovarian cancer treatment.

Clearer Horizons: The latest advances in clear cell ovarian cancer treatment.

Journal: Cancer treatment reviews

Published: April 22, 2025

Controversies in the management of mucinous ovarian tumors.

Controversies in the management of mucinous ovarian tumors.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: January 15, 2025

Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study).

Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study).

Journal: Current oncology (Toronto, Ont.)

Published: December 13, 2024

Showing 1-12 of 54

Last Updated: 09/26/2026